Marijuana Rescheduling Contradiction
DEA's Own Hearing Record Could Challenge Federal Marijuana Rescheduling Decision
The federal marijuana rescheduling hearing wrapped up on August 17, 2026 — but the legal fight is just beginning. Access Newswire reports that Administrative Law Judge Derek Julius must now decide what the hearing record actually proves, and the answer may surprise both sides of the debate.
The post-hearing briefs suggest the federal government built a record it will struggle to defend. According to Newswire, the evidence may not cleanly support moving marijuana to Schedule III — and could instead point toward a stricter Schedule II classification.
HHS Used a New Test Nobody Agreed on Before
The Department of Health and Human Services recommended Schedule III in 2023. To get there, it used a brand-new two-part test. That test asked whether state medical marijuana programs showed widespread real-world use, and whether any credible science backed at least one medical use. Voice of Alexandria notes this was a deliberate break from the traditional method the DEA had used for decades.
The problem is that no other federal agency endorsed this new framework before HHS applied it. DEA never signed off on it. That gap between what HHS decided and how DEA evaluates drugs is now at the center of the legal record Judge Julius must sort through.
DEA's Own Scientist Said Marijuana Fails the Old Test
DEA pharmacologist Dr. Luli Akinfiresoye testified during the hearing. Her conclusion was direct: marijuana fails the agency's traditional five-part scientific evaluation. She raised specific concerns — diversion from state marijuana systems, inconsistent product potency, and broader public-health risks. Finance Yahoo reported that her testimony put the government in an awkward spot.
That awkward spot is this: the DEA's own scientific witness said marijuana would not pass the DEA's own standard. If that is true, the agency must explain why it changed its method — and why a different method should now apply to this specific drug and not others.
Schedule II Could Be the Unintended Outcome
Most public debate has focused on two outcomes: keep marijuana in Schedule I or move it to Schedule III as HHS proposed. But Newswire reports the record may quietly support a third path — Schedule II. That would be stricter than the proposed change, treating marijuana more like oxycodone or fentanyl rather than anabolic steroids.
A Schedule II outcome would satisfy some of DEA's scientific concerns while still acknowledging medical use. It would also leave marijuana tightly controlled at the federal level, a far cry from what cannabis advocates hoped for when rescheduling was first proposed.
Judge Julius Now Holds the Key Decision
ALJ Derek Julius will now weigh all of the testimony and submit a recommended ruling. Access Newswire notes that his job is to determine what the full evidentiary record actually supports — not simply to rubber-stamp the HHS recommendation. That distinction matters enormously here.
The core tension is clear. HHS used a new framework to reach Schedule III. DEA's own experts said marijuana fails the old framework. Judge Julius must decide which framework is legally valid. His recommendation will shape federal marijuana policy for years — and may force a reckoning the government did not expect when this process began.
Sentiment
NeutralPublishers
4
Articles
3
Reach
4
